Interview with Tushar Pandey, SimBioSys Inc., CEO

Tushar Pandey, Chief Executive Officer at SimBioSys Inc., spoke with The News-Gazette on July 21, 2019, about what he does for the company and what the company is accomplishing. The company’s work focuses on cancer, and the SimBioSys team has “created a platform to computationally simulate tumor response to drug regimens to help oncologists in treatment planning phase.” A patient’s tumor can be made virtual, which allows for deeper understanding that impacts drug delivery, chemical interactions, and metabolism. Essentially, a cancer is modeled in order to monitor its behavior.

The company has a complete product for early-stage breast cancer, and clinical trials are already underway. SimBioSys is also working with the U.S. Food and Drug Administration to gain regulatory approval for their device so it can be used in medical settings. The goal of the company is to have a complete suite for all solid tumors within the next few years, and the first cancer targeted will be lung cancer. Initial work was funded by a grant from the National Cancer Institute and from angel investors, and SimBioSys aims to secure another round of funding in late 2019 to speed up their work.

To learn more about SimBioSys, click HERE.